SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

YKL-06-061

Item No. 41721

CAS Registry No.:	2172617-15-9
Formal Name:	1-cyclobutyl-3-(2,6-dimethylphenyl)-3,4-dihydro-7-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-pyrimido[4,5-d]pyrimidin-2(1H)-one
MF:	$C_{30}H_{37}N_7O_2$
FW:	527.7
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

YKL-06-061 is supplied as a solid. A stock solution may be made by dissolving the YKL-06-061 in the solvent of choice, which should be purged with an inert gas. YKL-06-061 is sparingly soluble (1-10 mg/ml) in chloroform and slightly soluble (0.1-1 mg/ml) in acetonitrile.

Description

YKL-06-061 is an inhibitor of salt-inducible kinase 1 (SIK1), SIK2, and SIK3 (IC_{50}s = 6.56, 1.77, and 20.5 nM, respectively).[1] It is selective for these SIKs over a panel of 468 additional kinases at 1 µM but does inhibit FRK, CSF1R, p38α, p38β, EphB1, and TNK2 (IC_{50}s = 1.1, 9.66, 10.1, 9.64, 16.4, and 10.5 nM, respectively) and to a lesser extent KIT, Src, BRK, PDGFRβ, and NLK (IC_{50}s = 153, 58.8, 24.1, 103, and 132 nM, respectively). YKL-06-061 (37.5 mM) induces pigmentation in human breast skin explants. *In vivo*, YKL-06-061 (20 mg/kg) decreases seizure severity in a mouse model of epilepsy induced by pentylenetetrazole (PTZ; Item No. 18682).[2]

References

1. Mujahid, N., Liang, Y., Murakami, R., *et al.* A UV-independent topical small-molecule approach for melanin production in human skin. *Cell Rep.* **19(11)**, 2177-2184 (2017).
2. Peng, L., Li, C., Tang, X., *et al.* Blocking salt-inducible kinases with YKL-06-061 prevents PTZ-induced seizures in mice. *Brain Behav.* **13(12)**, e3305 (2023).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/17/2024

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM